Canaccord raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $441 from $411 and keeps a Hold rating on the shares. The firm updated its model following Q4 rsults after they delivered its familiar top and bottom ine beat, though Trikafta revenue came in slightly below consensus and Alyftrek slightly above.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $607 from $606 at Barclays
- Vertex Pharmaceuticals price target raised to $591 from $518 at H.C. Wainwright
- Vertex Pharmaceuticals Signals Confident Growth Beyond CF
- Vertex Pharmaceuticals price target raised to $570 from $564 at Morgan Stanley
- Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank